Company News

Aragon Pharmaceuticals Inc., a company that develops drugs to treat hormone-driven cancers, announced that the first patient has been hosed in the clinical study of ARN-810 (Phase 1), which is categorized as an oral selective estrogen receptor degrader to treat breast cancer.

Aragon Pharmaceuticals Inc., a company that develops drugs to treat hormone-driven cancers, announced that the first patient has been hosed in the clinical study of ARN-810 (Phase 1), which is categorized as an oral selective estrogen receptor degrader to treat breast cancer.

As quoted in the press release:

The Phase 1 dose escalation study is designed to assess safety and tolerability of ARN-810. The study will be conducted at Vanderbilt University, Mass General Hospital and Memorial Sloan-Kettering Cancer Center.

Click here to read the full Aragon Pharmaceuticals Inc. press release.

MARKETS

Markets
TSX20276.53+95.93
TSXV669.24-9.26
DOW34145.61+233.17
S&P 5004304.22+7.08
NASD13099.77-28.28
ASX7064.30+31.80

COMMODITIES

Commodities
Gold1775.70-2.67
Silver20.14-0.10
Copper3.63+0.01
Palladium2154.00+17.43
Platinum938.00+8.00
Oil86.56-2.85
Heating Oil3.43+0.02
Natural Gas9.36+0.63

DOWNLOAD FREE REPORTS

×